Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

170.69
+2.811.67%
Post-market: 170.65-0.0400-0.02%19:30 EDT
Volume:1.92M
Turnover:324.20M
Market Cap:22.91B
PE:-48.72
High:170.85
Open:167.25
Low:165.01
Close:167.88
52wk High:176.58
52wk Low:53.40
Shares:134.20M
Float Shares:129.78M
Volume Ratio:0.71
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-102.78
PE(LYR):-51.41

Loading ...

Guardant Health Price Target Announced at $175.00/share by Bernstein

Dow Jones
·
Jun 26

GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM

TIPRANKS
·
Jun 26

U.S. Research Roundup-american Tower, H.B. Fuller Company, TD Synnex

Reuters
·
Jun 26

Movement Alert|Guardant Health Rises 5.05% in Regular Trading, Multiple Catalysts Drive Continued Rally

Market Focus
·
Jun 25

Guardant Health is Maintained at Overweight by Barclays

Dow Jones
·
Jun 24

Guardant Health price target raised to $150 from $120 at Barclays

TIPRANKS
·
Jun 24

Guardant Health director Myrtle S. Potter disposes of 1,556 common shares worth $204,084.96

Reuters
·
Jun 24

Hikma joins Guardant Health as platinum sponsor at UAE International Oncology Forum IOF 2026

Reuters
·
Jun 22

Guardant Health shareholders elect directors at annual meeting

Reuters
·
Jun 19

Living Longer Is Big Business. These Stocks Will Benefit. -- Barrons.com

Dow Jones
·
Jun 19

What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders

Simply Wall St.
·
Jun 18

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH)

TIPRANKS
·
Jun 17

U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower

Reuters
·
Jun 17

Guardant Health Inc : Jefferies Raises Target Price to $150 From $130

THOMSON REUTERS
·
Jun 17

Guardant Health director Tariq Musa disposes of 116 common shares for $15,102.04

Reuters
·
Jun 17

Guardant Health CIO Kumud Kalia sells 3,418 shares worth $445,156.57

Reuters
·
Jun 16

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

GlobeNewswire
·
Jun 15

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

GlobeNewswire
·
Jun 15

Guardant Health CIO Kumud Kalia sells 5,000 common shares worth $652,030.00

Reuters
·
Jun 13

Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says

MT Newswires Live
·
Jun 12